Test Price
650 AED✅ Home Collection Available
t(12;21)(p13;q22) ETV6-RUNX1 (TEL-AML1) PCR Qualitative Test in UAE | 650 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The qualitative ETV6-RUNX1 (TEL-AML1) PCR test detects the t(12;21) chromosomal translocation, the most common genetic abnormality in childhood B-cell acute lymphoblastic leukemia (ALL), critical for diagnosis and risk stratification. This test identifies the genetic fusion between ETV6 and RUNX1 genes caused by t(12;21) translocation, which occurs in approximately 25% of pediatric B-ALL cases. It is essential for confirming the favorable-risk genetic subgroup and influencing chemotherapy protocols, often allowing reduced-intensity treatment.
Test Comparison: Our Precision vs. Conventional Cytogenetics
| Feature | Our Test (Real-Time PCR) | Conventional Cytogenetics |
|---|---|---|
| Methodology | Reverse Transcriptase qPCR (ETV6-RUNX1 specific) | Karyotyping / FISH |
| Sensitivity | 99.9% (detects low-level fusion transcript) | ~90% (limited by cell culture and resolution) |
| Turnaround Time | 3 working days | 7–14 days |
| Clinical Utility | Directs targeted therapy and MRD monitoring | Broad chromosomal picture, slower |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA Registration ID: 9294403) shares: As a medical geneticist, I recognise the profound impact that precise molecular diagnosis has on childhood leukemia management. This PCR test provides definitive detection of the ETV6-RUNX1 fusion, enabling accurate risk classification and tailored therapeutic strategies. It must, however, be interpreted within the complete clinical and hematological context for optimal patient outcomes.
Advisory – Medication Continuity
Do not discontinue prescribed medication without consulting your doctor. Premature alteration of therapy may compromise treatment outcomes. Always discuss test results with your hematologist or oncologist before making any changes to your treatment plan.
Exclusion Criteria & Safety Alerts
- Exclusion: Active severe infection, hemodynamic instability, or high bleeding risk during bone marrow aspiration.
- ER Red Flag: Sudden high fever above 38.5°C, uncontrolled bleeding, or severe pain at collection site post-procedure requires immediate emergency care.
- Logistics Note: Sample must be transported refrigerated at 2–8°C; frozen specimens will be rejected.
Patient FAQ & Clinical Guidance
1. What is the ETV6-RUNX1 PCR test and why is it performed?
Snippet: This test detects ETV6-RUNX1 fusion gene, a critical marker in childhood B-cell acute lymphoblastic leukemia, guiding precise diagnosis and risk stratification.
The test identifies the genetic fusion between ETV6 and RUNX1 genes caused by t(12;21) translocation, which occurs in approximately 25% of pediatric B-ALL cases. It is essential for confirming the favorable-risk genetic subgroup and influencing chemotherapy protocols, often allowing reduced-intensity treatment. Regular follow-up qPCR may be used for monitoring minimal residual disease.
2. How is the sample collected and what are the requirements?
Snippet: A bone marrow aspirate or EDTA whole blood specimen is collected under sterile conditions within a hospital setting; refrigeration at 2–8°C is required.
A trained hematologist performs a bone marrow aspiration, or a phlebotomist draws whole blood into a lavender-top EDTA tube. The sample must be shipped refrigerated at 2–8°C within 24 hours; freezing destroys the RNA and invalidates the assay. A completed clinical history form is mandatory for processing.
3. What does a positive result mean and what are the next steps?
Snippet: A positive result indicates the presence of ETV6-RUNX1 fusion, classifying the leukemia as a favorable-risk subtype requiring specific therapy.
A positive detection confirms ETV6-RUNX1-positive B-ALL, generally associated with excellent prognosis under modern treatment protocols. The oncologist will integrate this finding with minimal residual disease (MRD) studies and other risk factors to tailor chemotherapy. Regular follow-up qPCR may be used for monitoring treatment response and early detection of relapse.
UAE Regulatory & Data Privacy Adherence
Our Compliance Framework
This service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. All laboratory processes adhere to DHA and MOHAP standards for genetic and molecular diagnostic testing.
Clinical & Logistical Metadata
| Test Name | t(12;21)(p13;q22) ETV6-RUNX1 (TEL-AML1) PCR Qualitative Test |
| Price (AED) | 650 AED |
| Turnaround Time | 3 Working Days |
| Sample Type / Matrix | Bone Marrow Aspirate or EDTA Whole Blood (Hospital Extraction Only) |
| Methodology Used | Reverse Transcriptase Quantitative PCR (RT-qPCR) |
| ICD-10-CM Code | C91.00 |
| LOINC Code | 60515-4 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab Branding: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians